Rhythm Pharmaceuticals (1RV) Stock Forecast & Price Target
1RV Analyst Ratings
Strong Buy
14Buy1Hold0Sell
Based on 15 analysts giving stock ratings to Rhythm Pharmaceuticals in the past 3 months
1RV Stock 12 Month Forecast
Average Price Target
EUR 130.63▲(57.39% Upside)Based on 15 Wall Street analysts offering 12 month price targets for Rhythm Pharmaceuticals in the last 3 months. The average price target is EUR 130.63 with a high forecast of EUR 183.84 and a low forecast of EUR 107.09. The average price target represents a 57.39% change from the last price of EUR 83.00.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 183.84
AverageEUR 130.63
LowEUR 107.09
Highest Price TargetHighestEUR 183.84Average Price TargetEUR 130.63Lowest Price TargetLowestEUR 107.09
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Samantha Semenkow | Citi | EUR 127.61 | buy | 53.75%Upside | Reiterated | 10/28/26 | ||
| Seamus Fernandez | Guggenheim | EUR 127.61 | buy | 53.75%Upside | Reiterated | 10/19/26 | ||
| Priyanka Grover | J.P. Morgan | EUR 130.29→EUR 129.40 | buy | 55.90%Upside | Assigned | 10/15/26 | ||
| Sharon Zackfia | William Blair | EUR 183.84 | buy | 121.49%Upside | Initiated | 10/15/26 | ||
| Ram Selvaraju | H.C. Wainwright | EUR 93.70→EUR 116.01 | buy | 39.77%Upside | Reiterated | 10/12/26 | ||
| Tazeen Ahmad | Bank of America Securities | ― | buy | ― | Reiterated | 10/09/26 | ||
| Lisa Walter | RBC Capital | EUR 138.32→EUR 141.89 | buy | 70.95%Upside | Reiterated | 10/08/26 | ||
| Kalpit Patel | Wolfe Research | ― | buy | ― | Initiated | 09/17/26 | ||
| Basma Radwan | Leerink Partners | EUR 118.69 | buy | 43.00%Upside | Initiated | 09/14/26 | ||
| David Hoang | Deutsche Bank | EUR 107.09 | hold | 29.02%Upside | Initiated | 08/27/26 | ||
| Michael Ulz | Morgan Stanley | EUR 133.86 | buy | 61.28%Upside | Reiterated | 08/24/26 | ||
| Jonathan Wolleben | Citizens JMP | EUR 138.32→EUR 142.78 | buy | 72.03%Upside | Reiterated | 08/05/26 | ||
| Whitney Ijem | Canaccord Genuity | EUR 134.75→EUR 137.43 | buy | 65.58%Upside | Reiterated | 08/05/26 | ||
| Joseph Stringer | Needham | EUR 116.01 | buy | 39.77%Upside | Reiterated | 08/04/26 | ||
| Phil Nadeau | TD Cowen | EUR 116.01 | buy | 39.77%Upside | Assigned | 08/04/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Samantha Semenkow | 10/28/26 | EUR 127.61 | buy | 53.75%Upside | Reiterated | Citi | ||
| Seamus Fernandez | 10/19/26 | EUR 127.61 | buy | 53.75%Upside | Reiterated | Guggenheim | ||
| Priyanka Grover | 10/15/26 | EUR 130.29→EUR 129.40 | buy | 55.90%Upside | Assigned | J.P. Morgan | ||
| Sharon Zackfia | 10/15/26 | EUR 183.84 | buy | 121.49%Upside | Initiated | William Blair | ||
| Ram Selvaraju | 10/12/26 | EUR 93.70→EUR 116.01 | buy | 39.77%Upside | Reiterated | H.C. Wainwright | ||
| Tazeen Ahmad | 10/09/26 | ― | buy | ― | Reiterated | Bank of America Securities | ||
| Lisa Walter | 10/08/26 | EUR 138.32→EUR 141.89 | buy | 70.95%Upside | Reiterated | RBC Capital | ||
| Kalpit Patel | 09/17/26 | ― | buy | ― | Initiated | Wolfe Research | ||
| Basma Radwan | 09/14/26 | EUR 118.69 | buy | 43.00%Upside | Initiated | Leerink Partners | ||
| David Hoang | 08/27/26 | EUR 107.09 | hold | 29.02%Upside | Initiated | Deutsche Bank | ||
| Michael Ulz | 08/24/26 | EUR 133.86 | buy | 61.28%Upside | Reiterated | Morgan Stanley | ||
| Jonathan Wolleben | 08/05/26 | EUR 138.32→EUR 142.78 | buy | 72.03%Upside | Reiterated | Citizens JMP | ||
| Whitney Ijem | 08/05/26 | EUR 134.75→EUR 137.43 | buy | 65.58%Upside | Reiterated | Canaccord Genuity | ||
| Joseph Stringer | 08/04/26 | EUR 116.01 | buy | 39.77%Upside | Reiterated | Needham | ||
| Phil Nadeau | 08/04/26 | EUR 116.01 | buy | 39.77%Upside | Assigned | TD Cowen |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Rhythm Pharmaceuticals
3 Months
Success Rate18/25 ratings generated profit
72%
Average Return
+13.78%
Copying Whitney Ijem's trades and holding each position for 3 Months would result in 72.00% of your transactions generating a profit, with an average return of +13.78% per trade.
1 Year
Success Rate33/38 ratings generated profit
87%
Average Return
+67.37%
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 86.84% of your transactions generating a profit, with an average return of +67.37% per trade.
2 Years
Success Rate33/38 ratings generated profit
87%
Average Return
+152.96%
Copying Joseph Stringer's trades and holding each position for 2 Years would result in 86.84% of your transactions generating a profit, with an average return of +152.96% per trade.
1RV Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 1 | 7 | 7 |
| Buy | 22 | 22 | 20 | 17 | 5 |
| Hold | 0 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 30 | 29 | 22 | 25 | 12 |
In the current month, 1RV has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1RV average Analyst price target in the past 3 months is 130.63.
1RV Financial Forecast
HighEUR -0.48
ConsensusEUR -0.64
LowEUR -0.76
1RV Earnings Forecast
Next quarter’s earnings estimate for 1RV is -EUR 0.64 with a range of -EUR 0.76 to -EUR 0.48. The previous quarter’s EPS was -EUR 0.65. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighEUR 87.3M
ConsensusEUR 76.6M
LowEUR 69.8M
1RV Sales Forecast
Next quarter’s sales forecast for 1RV is EUR 76.61M with a range of EUR 69.84M to EUR 87.33M. The previous quarter’s sales results were EUR 63.80M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
1RV Stock Forecast FAQ
What is DE:1RV’s average 12-month price target, according to analysts?
Based on analyst ratings, Rhythm Pharmaceuticals’s 12-month average price target is €130.63.
What is DE:1RV’s upside potential, based on the analysts’ average price target?
Rhythm Pharmaceuticals has 57.39% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Rhythm Pharmaceuticals a Buy, Sell or Hold?
Rhythm Pharmaceuticals has a consensus rating of Strong Buy, which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
What is Rhythm Pharmaceuticals’s share price target?
The average share price target for Rhythm Pharmaceuticals is €130.63. This is based on 15 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €183.84, and the lowest forecast is €107.09. The average share price target represents a 57.39% increase from the current price of €83.
What do analysts say about Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Street analysts.
How can I buy shares of Rhythm Pharmaceuticals?
To buy shares of DE:1RV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
